Tumors are not passive targets. They actively reshape the environment around them, converting the body’s own immune cells into defenders of the cancer rather than attackers of it. This is one of the central problems in cancer immunotherapy, and it is why even promising treatments often stall. A research team at the University of Adelaide has developed an approach that addresses this problem directly: a delivery system that uses engineered nanoparticles to carry mRNA therapy into the specific immune cells that tumors have co-opted, reprogramming them from the inside.
The Tumor’s Trick: Turning Defenders Into Suppressors
To understand why this matters, it helps to understand what tumors actually do to the immune system. The body’s immune cells are capable of identifying and destroying cancerous cells. Tumors, however, can emit signals that interfere with this process. One key mechanism involves a class of immune cells called tumor-associated macrophages. Under normal conditions, macrophages are part of the body’s defense network. Inside a tumor’s environment, they can be rewired by the cancer to block T cells, which are among the body’s primary weapons against malignant tissue.
This is what most coverage of cancer immunotherapy misses: the obstacle is not simply that the immune system fails to recognize the tumor. In many cases, it recognizes it but cannot act. The tumor has effectively placed its own security force inside the immune system.
Professor Chunxia Zhao, who led the research published in Science Advances, described the core challenge plainly: the immune system may be capable of attacking a tumor, but the tumor environment can stop those immune cells from doing their job.
The Delivery Problem: Getting mRNA to the Right Cell
The therapeutic concept at the heart of this research is relatively straightforward. The mRNA used in the therapy carries instructions for producing CXCL9, a chemical signal that recruits T cells to the tumor site. If macrophages that have been reprogrammed by the tumor can be flipped back into an active immune state, they can begin calling in reinforcements rather than blocking them.
mRNA technology has advanced considerably since it entered public awareness through Covid vaccines, and its application to cancer treatment has been an active area of development. The challenge here is not the mRNA itself. It is delivery. Activating the immune system indiscriminately carries real risks: too much immune activity in the wrong places can cause dangerous side effects.
The Adelaide team’s solution was a targeted nanoparticle system they described as “smart.” Like standard mRNA therapies, the molecules are encased in a lipid nanoparticle, a fatty structure that helps them enter cells. What makes this version different is an additional targeting layer: the nanoparticles are studded with antibodies that bind specifically to TREM2, a protein found on the surface of the immunosuppressive macrophages that tumors recruit. This means the therapy does not simply reach the tumor region. It enters only the cells within that region that have been co-opted by the cancer.
The nanoparticles also carried a second payload: resiquimod, a drug that stimulates certain immune pathways. In laboratory results, macrophages that had previously been in a suppressed state began producing CXCL9 and other markers of immune activation. One such marker, NOS2, increased in expression by a factor of 89.5. Signals associated with immune suppression decreased notably.
In mouse models with aggressive breast cancer, three doses of the treatment slowed tumor growth. CXCL9 concentration in treated subjects was approximately four times higher than in the control group. T cell activity was detected. The proportion of macrophages with immunosuppressive characteristics dropped by 63 percent. The researchers also tested the therapy alongside existing treatments called immune checkpoint inhibitors. The combination did not further reduce tumor size, but it did increase the presence of different types of T cells within tumors and nearby lymph nodes, a finding associated with the potential for a more durable immune response.
No negative effects on other organs were detected, though the researchers were explicit that further safety studies are needed before human trials can be considered.
Why Precision Delivery Changes the Equation
The broader significance of this research is not any single result. It is the demonstration that mRNA and nanoparticle technology can be engineered to act with a level of cellular specificity that was not previously achievable in this context. Targeting a protein like TREM2, present specifically on immunosuppressive macrophages within the tumor environment, means the therapy can intervene at a precise point in the immune suppression chain without disrupting the rest of the system.
This matters for how cancer treatment is likely to evolve. Combination therapies are already standard practice, and the ability to add a precisely targeted reprogramming layer to existing immunotherapy regimens opens a different kind of design space. Rather than simply adding more immune activation, clinicians could potentially restore the immune system’s own architecture within the tumor environment first, then allow other treatments to operate in a less hostile context.
Professor Zhao framed the result as a proof of concept: evidence that the approach is mechanistically sound, not a finished treatment. Significant work remains before this could be considered for patients.
In Short
A University of Adelaide research team has developed nanoparticles that deliver mRNA therapy directly to immunosuppressive macrophages inside tumors, reprogramming them to recruit T cells rather than block them. In mouse models, the treatment reduced immunosuppressive macrophages by 63 percent and raised CXCL9 concentration to roughly four times that of the control group. The research demonstrates that cellular-level targeting within the tumor environment is achievable with current nanoparticle technology. Human trials are not yet on the horizon, but the proof of concept is significant: it shows that the immune system’s own machinery, even after being co-opted by a tumor, can potentially be reclaimed.
Based on reporting from Wired Science.
Read the original study.